ENTBF (Entheon Biomedical) Accounts Receivable: $0.00 Mil (As of May. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Entheon Biomedical Accounts Receivable?

Entheon Biomedical ENTBF Accounts Receivable is $0.00 Mil as of May. 2026.

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Entheon Biomedical's accounts receivables for the quarter that ended in May. 2026 was $0.00 Mil.

Accounts receivable can be measured by Days Sales Outstanding.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Entheon Biomedical's Net-Net Working Capital per share for the quarter that ended in May. 2026 was $0.01.

Entheon Biomedical Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

Entheon Biomedical's Days Sales Outstanding for the quarter that ended in May. 2026 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=0/0*91
=

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Entheon Biomedical's accounts receivable are only considered to be worth 75% of book value:

Entheon Biomedical's Net-Net Working Capital Per Share for the quarter that ended in May. 2026 is calculated as:

Net-Net Working Capital Per Share
=(Cash And Cash Equivalents+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(0.236+0.75 * 0+0.5 * 0-0.031
-0-0)/13.859
=0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.

Entheon Biomedical Accounts Receivable Related Terms

Entheon Biomedical Accounts Receivable Historical Data

* Premium members only.

The historical data trend for Entheon Biomedical's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Entheon Biomedical Accounts Receivable Chart

Entheon Biomedical Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Nov21 Nov22 Nov23 Nov24 Nov25
Accounts Receivable
Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 0.00

Entheon Biomedical Quarterly Data
Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26 May26
Accounts Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Entheon Biomedical Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.

Frequently Asked Questions Learn more about Accounts Receivable →
What does a Accounts Receivable of $0.00 Mil mean?
Entheon Biomedical (ENTBF) has a Accounts Receivable of $0.00 Mil as of May. 2026. Accounts receivable is the amount a company expects to receive from credit-extending customers. View historical data on Entheon Biomedical and its competitors.
Is Entheon Biomedical's Accounts Receivable too high?
Entheon Biomedical's current Accounts Receivable is $0.00 Mil.
How does Entheon Biomedical's Accounts Receivable compare to VRTX and REGN?
Entheon Biomedical's Accounts Receivable of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Receivable for a Biotechnology company?
A good Accounts Receivable depends on the Biotechnology industry context. However, Accounts Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Receivable mean?
A high Accounts Receivable can signal that a stock is expensive relative to its fundamentals. Accounts receivable is the amount a company expects to receive from credit-extending customers. View historical data on Entheon Biomedical and its competitors. Entheon Biomedical's current Accounts Receivable is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Entheon Biomedical stock overvalued right now?
Entheon Biomedical (ENTBF) has a current Accounts Receivable of $0.00 Mil. The current Accounts Receivable is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Receivable calculated?
Accounts Receivable is calculated from a company's financial statements. For Entheon Biomedical (ENTBF), the current Accounts Receivable is $0.00 Mil as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Entheon Biomedical Business Description

Other Exchanges 1XU:GermanyENBI.X:Canada
Address 999 West Broadway Street, Suite 720, Vancouver, BC, CAN, V5Z 1K5
Entheon Biomedical Corp is a biotechnology research and development company focused on treating addiction and substance use disorders.